Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy
Authors
Keywords
-
Journal
Cancers
Volume 5, Issue 4, Pages 64-91
Publisher
MDPI AG
Online
2013-01-21
DOI
10.3390/cancers5010064
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II study of cetuximab (Cetuximab) with cisplatin and capecitabine (Xeloda) as 1st line treatment in advanced gastric cancer
- (2017) X. Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer
- (2017) P. C. Enzinger et al. JOURNAL OF CLINICAL ONCOLOGY
- ATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer—Final results of a multicentre phase II trial by the AGITG
- (2017) N. C. Tebbutt et al. JOURNAL OF CLINICAL ONCOLOGY
- Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: First results of a multicenter phase II trial (AGMT Gastric- 2
- (2017) E. Woell et al. JOURNAL OF CLINICAL ONCOLOGY
- C-met as a therapeutic target for metastatic potential of gastric cancer.
- (2017) H. Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer.
- (2017) P. C. Enzinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of a phase II study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ).
- (2017) Z. A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer.
- (2017) T. Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071).
- (2017) A. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC).
- (2017) Y. Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC).
- (2017) Y. Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II.
- (2017) I. Chau et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil–based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results.
- (2017) Y. H. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).
- (2017) Tom Samuel Waddell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1.
- (2017) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel targeted agents for gastric cancer
- (2012) Lian Liu et al. Journal of Hematology & Oncology
- A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
- (2011) J. A. Chan et al. ANNALS OF ONCOLOGY
- Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer
- (2011) Taroh Satoh et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review
- (2011) Flora Zagouri et al. CANCER TREATMENT REVIEWS
- An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
- (2011) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the human EGFR family in esophagogastric cancer
- (2011) Alicia Okines et al. Nature Reviews Clinical Oncology
- Anti-HER agents in gastric cancer: from bench to bedside
- (2011) Lorenzo Fornaro et al. Nature Reviews Gastroenterology & Hepatology
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Critical appraisal of trastuzumab in treatment of advanced stomach cancer
- (2011) Judith Meza-Junco et al. Cancer Management and Research
- HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain
- (2011) E. U. Cidon et al. Journal of Oncology
- Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
- (2010) S. Rao et al. ANNALS OF ONCOLOGY
- A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
- (2010) B. F. El-Rayes et al. ANNALS OF ONCOLOGY
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors
- (2010) Matthew D. Galsky et al. INVESTIGATIONAL NEW DRUGS
- Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
- (2010) Chul Kim et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- (2010) Yung-Jue Bang et al. INVESTIGATIONAL NEW DRUGS
- Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
- (2010) Alicia F.C. Okines et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
- (2010) Weijing Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
- (2010) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
- (2010) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer
- (2010) Cristina P. Rodriguez et al. Journal of Thoracic Oncology
- Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)
- (2010) Philip J. Gold et al. Journal of Thoracic Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
- (2009) S-W Han et al. BRITISH JOURNAL OF CANCER
- Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
- (2009) C Pinto et al. BRITISH JOURNAL OF CANCER
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
- (2009) E. Martinelli et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Current status of cediranib: the rapid development of a novel anti-angiogenic therapy
- (2009) Colin R Lindsay et al. Future Oncology
- A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
- (2009) Chul Kim et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
- (2008) S Rao et al. BRITISH JOURNAL OF CANCER
- The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
- (2008) Jin Won Kim et al. CANCER LETTERS
- Cetuximab With Concurrent Chemoradiation for Esophagogastric Cancer: Assessment of Toxicity
- (2008) Howard Safran et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation